<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01480778</url>
  </required_header>
  <id_info>
    <org_study_id>LEEUNI0811</org_study_id>
    <nct_id>NCT01480778</nct_id>
  </id_info>
  <brief_title>Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®.</brief_title>
  <official_title>Pharmacodynamic Assessment to Drug Ciclo 21 (Levonorgestrel + Ethinyl Estradiol) Market by União Química Farmacêutica Nacional S/A Compared to Drug Nordette of Wieth Indústria Farmacêutica Ltda.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>União Química Farmacêutica Nacional S/A</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Azidus Brasil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the pharmacodynamic profile of the drug Ciclo 21 ®, marketed by União Química
      Farmacêutica Nacional S / A, compared to the drug Nordette ® Laboratory Wyeth Pharmaceutical
      Ltda. Through the modulation of hormonal response (inhibition of the pituitary) evidenced by
      measurement serum LH and FSH for 28 days, as well as by the absence of follicle formation
      demonstrated by transvaginal ultrasound examinations
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      secondary objective

        -  Evaluation of the safety aspects of medicines such as type, frequency and intensity of
           adverse events between groups during the 28 day trial.

      exploratory objective

        -  Evaluation of the pharmacokinetics of the drug administered through the dosage of serum
           hormone levonorgestrel and ethinyl estradiol for 28 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint will be the changes in FSH and LH secretion induced by daily administration of the drug for 21 consecutive days during the 28 days of participation in the trial.</measure>
    <time_frame>1, 2, 4, 7, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 24 and 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of drugs: type, frequency and intensity of adverse events between groups during the 28 day trial. Exploratory investigation of the pharmacokinetics of the drug administered through the dosage of hormones in serum LNG and EE2 for 28 days.</measure>
    <time_frame>PK: 1 (0, 1, 2, 3, 4, 5, 6, 12 e 18 hours after administration), 2, 7, 14, 21 and 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Irregular Periods</condition>
  <arm_group>
    <arm_group_label>LNG+EE2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pill test contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nordette</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pill comparator contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LNG+EE2</intervention_name>
    <description>Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.</description>
    <arm_group_label>LNG+EE2</arm_group_label>
    <other_name>Ciclo 21</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nordette</intervention_name>
    <description>Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.</description>
    <arm_group_label>Nordette</arm_group_label>
    <other_name>LNG+EE2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Comply with all study procedures, sign, initial and date back, of their own free will,
             the IC;

          2. Women aged between 18 and 35 years, regardless of race and class;

          3. Make use of safe non-hormonal method of contraception such as tubal ligation,
             non-hormonal IUDs or condoms, or be hysterectomised or be vasectomized sexual partner;

          4. Examination of Beta-HCG negative;

          5. with regular menstrual cycles every 24 to 32 days, at least the last three months;

          6. present normal Pap test (current or during the past 02 years);

          7. Present or vaginal examination found that the changes do not interfere in the study;

          8. present levels of FSH, LH, estradiol and TT for the normal menstrual cycle, as well as
             normal transvaginal sonographic reports.

        Exclusion Criteria:

          1. Provide a contraindication to the use of steroids;

          2. Use regular or prediction of drugs that interfere with the metabolism of the
             investigational products, such as antibiotics, anticonvulsants, anticoagulants and
             hypoglycemic drugs;

          3. smokers or have stopped smoking less than 12 months;

          4. Diabetic;

          5. Toxic-dependent;

          6. BMI &lt;18 and&gt; 25;

          7. have made use of topical or systemic sex hormone for at least two months before the
             start of the study;

          8. Background and personal or family history of thrombosis or bleeding disorders or
             vascular disorders or cardiovascular disease;

          9. Laboratory tests, gynecological ultrasound or changed, the medical criteria;

         10. Individuals with allergies or rheumatic diseases for which is indicated the use of
             cortico-steroid medication;

         11. carry any endocrine changes, especially pituitary and gonadal and / or who are advised
             to use hormones;

         12. with lesions or abnormalities suspected or confirmed in the gonads.

         13. personal or family history of breast cancer or other hormone-dependent breast
             pathology;

         14. with hypertension or diabetes mellitus (for drug interactions between the COC and
             hypoglycemic agents and antihypertensives);

        a) History of nausea with oral use of COCs; p) Any condition that may interfere with the
        discretion of the investigator in the study data as well as being the measurement of the
        study be deleterious to the patient.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Frederico, PI</last_name>
    <role>Principal Investigator</role>
    <affiliation>LAL Clinica Pesquisa e Desenvolvimento Ltda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LAL Clínica Pesquisa e Desenvolvimento Ltda</name>
      <address>
        <city>Valinhos</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Twaddle NC, Churchwell MI, Newbold RR, Delclos KB, Doerge DR. Determination using liquid-chromatography-electrospray tandem mass spectroscopy of ethinylestradiol serum pharmacokinetics in adult Sprague-Dawley rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Aug 15;793(2):309-15.</citation>
    <PMID>12906905</PMID>
  </results_reference>
  <results_reference>
    <citation>Benagiano G, Carrara S, Filippi V. Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives. Patient Prefer Adherence. 2009 Nov 3;3:131-43.</citation>
    <PMID>19936155</PMID>
  </results_reference>
  <results_reference>
    <citation>Crosignani PG, Testa G, Vegetti W, Parazzini F. Ovarian activity during regular oral contraceptive use. Contraception. 1996 Nov;54(5):271-3.</citation>
    <PMID>8934059</PMID>
  </results_reference>
  <results_reference>
    <citation>van Heusden AM, Fauser BC. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. Contraception. 1999 Apr;59(4):237-43.</citation>
    <PMID>10457868</PMID>
  </results_reference>
  <results_reference>
    <citation>Rossmanith WG, Steffens D, Schramm G. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity. Contraception. 1997 Jul;56(1):23-30.</citation>
    <PMID>9306028</PMID>
  </results_reference>
  <results_reference>
    <citation>Hemrika DJ, Slaats EH, Kennedy JC, de Vries Robles-Korsen TJ, Schoemaker J. Pulsatile luteinizing hormone patterns in long term oral contraceptive users. J Clin Endocrinol Metab. 1993 Aug;77(2):420-6.</citation>
    <PMID>8345046</PMID>
  </results_reference>
  <results_reference>
    <citation>Kroll R, Reape KZ, Margolis M. The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol. Contraception. 2010 Jan;81(1):41-8. doi: 10.1016/j.contraception.2009.07.003.</citation>
    <PMID>20004272</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2011</study_first_submitted>
  <study_first_submitted_qc>November 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2011</study_first_posted>
  <last_update_submitted>March 2, 2016</last_update_submitted>
  <last_update_submitted_qc>March 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hormonal response, levonorgestrel, ethinyl estradiol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study data will be maked available after journal's approbation. The manuscript contained all of data it has been submitted.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

